BridgeMD
Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypothyroidism after Hemithyroidectomy: A Randomised Controlled Trial
EU CTIS ID: 2025-524175-23-00
What this study is testing
To evaluate whether postoperative treatment with LT4 leads to an improvement in kidney function - measured as change in eGFR - three months after HT, compared to standard care without LT4
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients referred for a first hemithyroidectomy
- TSH ≥2 mUI/L.
- eGFR > 30 mL/min/1.73m2.
- Age 18 years or above
- Ability to understand the study information and provide written informed consent.
- Able and willing to comply with study procedures and attend scheduled visits.
You likely can't join if
- Previous thyroid operation
- Initiated treatment with either ACE inhibitors, ARB or SGLT2 after surgery.
- Inability to understand Danish or provide informed consent.
- Participation in another interventional study that may interfere with outcomes.
- Planned total thyroidectomy or completion thyroidectomy during follow-up
- Treatment with Thycapzole or similar medication with direct effect on thyroid hormones.
See the full eligibility criteria
- Patients referred for a first hemithyroidectomy
- TSH ≥2 mUI/L.
- eGFR > 30 mL/min/1.73m2.
- Age 18 years or above
- Ability to understand the study information and provide written informed consent.
- Able and willing to comply with study procedures and attend scheduled visits.
- Previous thyroid operation
- Initiated treatment with either ACE inhibitors, ARB or SGLT2 after surgery.
- Inability to understand Danish or provide informed consent.
- Participation in another interventional study that may interfere with outcomes.
- Planned total thyroidectomy or completion thyroidectomy during follow-up
- Treatment with Thycapzole or similar medication with direct effect on thyroid hormones.
- Concomitant operation for primary hyperparathyroidism (PHPT).
- Pregnancy or plans of pregnancy in the postoperative period.
- Cancer treatment within the last three years.
- Use of narcotics or alcohol abuse.
- Severe other illness (psychiatric disorder, kidney disease with GFR < 30 etc.).
- Severe cardio-vascular disease (atrial fibrillation, heart failure etc.).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.